In the fight against cancer, drug therapy is an important measure, and effective anti-cancer drugs can help patients achieve a longer survival time
.
In recent years, new progress has been made in the field of anticancer drugs, and anticancer drugs at home and abroad have emerged
for a long time.
However, compared with expensive imported drugs, many patients pin their hopes on domestic anti-cancer drugs
.
In this context, in order to meet the growing demand, Chinese pharmaceutical companies are continuing to carry out research and development and innovation in anti-cancer drugs, and many new anti-cancer drugs
have emerged.
On November 10, Shanghai Yingli Pharmaceutical Co.
, Ltd.
announced that the company's self-developed new anti-cancer class 1 drug linperlisib has been approved by China's National Medical Products Administration (NMPA) on November 9, targeting the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) under the trade name Intaru.
It is understood that after the approval of marketing, Yingli Pharmaceutical will jointly promote the commercialization
of Intari in China.
Hengrui Pharmaceutical has extensive commercial operation experience and clinical development capabilities in China, and with the mature marketing system of Hengrui Pharmaceutical, Linplisset is expected to have better market feedback
.
In fact, in recent years, the scale of China's anti-tumor drug market has been expanding, and domestic new drugs are constantly emerging
.
Before Yingli Pharmaceutical, the first new anti-CD20 monoclonal antibody independently developed by Shenzhou Cell - "Anpingxi" repatumab has also been approved for marketing
.
Repatumab is the basic treatment for B-cell lymphoma
.
In terms of price, according to Beijing Daily, the current domestic new anti-CD20 monoclonal antibody is 10%-20% cheaper than commonly used imported drugs, and Shenzhou Cell will participate in medical insurance negotiations next year, and if it enters the national medical insurance catalog, it will further reduce the burden
on patients.
On the whole, under the issuance and implementation of a series of favorable pharmaceutical innovation policies and regulations, as well as the acceleration of new drug review and approval, China's anti-cancer new drug research and development has ushered in good development opportunities and ushered in more and more new breakthroughs
.
Incomplete statistics show that in the first half of the year, 30 innovative drugs were approved for marketing in China, of which 15 were anti-tumor drugs, accounting for 50%, involving gastric cancer, cholangiocarcinoma, cervical cancer, lung cancer, Hodgkin lymphoma, leukemia, prostate cancer, etc
.
It is worth mentioning that with the continuous emergence of domestic new drugs, the current trend of domestic anti-cancer drugs entering medical insurance is also becoming a trend
.
It is reported that in the results of the adjustment of the national medical insurance drug catalog in 2021, 18 anticancer drugs were included in the medical insurance reimbursement catalog, involving multiple cancers such as lung cancer, liver cancer, ovarian cancer and breast cancer, of which 11 drugs are domestic anticancer drugs
.
The industry believes that in the future, with the continuous acceleration of drug approval and the continuous listing of new drugs, more domestic anti-cancer drugs may be included in medical insurance and usher in a price
.
In general, from the current development of the anti-cancer drug market, it will still maintain rapid growth
.
However, it should be noted that although China has achieved a lot of results in anticancer drugs in recent years, there are also many needs and indications that have not been met, so enterprises still need to continuously promote the research and development and innovation
of new drugs and new targets.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
